Xenitra Locks in $30M Danone Deal With China’s Trillion Dollar Rockcheck Group
Xenitra secures $30 million Danone supply deal with Rockcheck Group
Xenitra Limited (ASX: XEN) has announced the Xenitra Danone Rockcheck Partnership through two agreements that significantly expand its strategic relationship with the Rockcheck Group. The first agreement targets sales of $30 million AUD (140 million RMB) in Danone products over a 12-month period commencing 1 May 2026, whilst the second establishes Xenitra’s Australian trading subsidiary as an authorised supplier to the multi-billion dollar Chinese conglomerate.
The agreements build on an existing relationship that commenced in 2023 and has already delivered more than $10 million AUD in FY26 sales to date. The Danone supply agreement includes an option to extend for a further 3 years, subject to successful completion of first quarter sales under the initial term.
The $30 million agreement represents approximately three times the current annual run rate with Rockcheck, providing revenue visibility through to 30 April 2027 with extension optionality that could lock in sales through to 2030.
| Metric | Detail |
|---|---|
| Agreement Value | $30m AUD (140m RMB) |
| Term | 1 May 2026 – 30 April 2027 |
| FY26 Sales to Date | >$10m AUD |
| Extension Option | 3 additional years |
| Relationship Commenced | 2023 |
When big ASX news breaks, our subscribers know first
Framework agreement unlocks broader B2B sales channel
The second agreement establishes Xenitra’s Australian trading subsidiary as an authorised supplier to the Rockcheck Group, creating a direct procurement pathway for all brands in the Xenitra portfolio. This framework agreement operates independently of the Danone supply deal and has strategic implications beyond nutritional products.
The authorisation means Xenitra’s brand partners can now access both the company’s established e-commerce network across major Chinese platforms and a direct B2B channel into Rockcheck Group companies. Products can be procured in Australia by Xenitra and sold directly into the conglomerate’s operations in China.
Rockcheck Group generates revenues exceeding 1 trillion RMB annually, with tens of billions of RMB in assets and operations spanning China and international markets. The group’s scale creates meaningful distribution optionality for current and prospective brand partners on the Xenitra platform.
The dual benefits of the framework agreement include:
- Direct B2B procurement channel into Rockcheck Group companies
- Complements existing e-commerce network across all major Chinese platforms
- Enhances value proposition for current and prospective brand partners
Who is Rockcheck Group?
Rockcheck Group is a major Chinese conglomerate headquartered in Tianjin, with origins in steel and now diversified across energy, logistics, technology, finance, and health and wellness sectors. Within its health business, the group focuses on nutritional and healthcare products, healthcare investment, and medical research support, whilst also undertaking public health initiatives.
The conglomerate has deployed hundreds of millions of RMB into health-related activities as part of its broader “health and culture” strategy aligned with China’s national priorities. Rockcheck’s health strategy combines capital investment, digital and real world capability, and philanthropy to participate in China’s rapidly expanding health and life sciences ecosystem.
The company’s expertise in sales and marketing of high-velocity nutritional products positions it as a strategic distribution partner for premium infant formula brands, including Danone’s range which holds a leading position in the Chinese market.
Management signals company positioned for growth
Chairman Dr Anthony Noble framed the expanded partnership as a foundational step in Xenitra’s multichannel strategy in China. The company has emerged from a period of board and management change, corporate rebranding, and cost rebasing, with management describing the Rockcheck partnership as the first step in executing a clearly defined strategy towards profitability.
Dr Anthony Noble, Chairman
“Further expanding our relationship with Rockcheck is a foundational step in our multichannel strategy in the China market. They are our most important nutritional products customer and growing sales in this segment is an important contributor to the company rapidly reaching profitable scale.”
Dr Noble validated the Australian subsidiary authorisation as a “step-change” in the company’s capacity to execute on high-volume B2B sales for brands entering the Chinese market. He noted the framework creates access into “a multi-hundred-billion dollar group of companies” for Xenitra’s brand partners.
The nutritionals business unit has been described as a cornerstone of revenues for the past two years. The expanded Danone agreement and broader supplier authorisation cement what management characterises as a firm foundation for this business unit heading into FY27.
The next major ASX story will hit our subscribers first
What this means for Xenitra’s investment case
The dual agreements address three key components of Xenitra’s investment thesis: revenue scale, channel diversification, and platform value for brand partners. The $30 million Danone agreement provides 12-month revenue visibility with 3-year extension optionality subject to first quarter performance, whilst the framework agreement creates a scalable B2B channel that can accommodate additional product lines.
Management has indicated that further product lines suitable for sale through Rockcheck may be added to the partnership agreement. This positions the framework as infrastructure that can support incremental revenue growth as new brand partners join the Xenitra platform or existing partners expand their product ranges.
Key catalysts flowing from the announcement include:
- $30 million revenue agreement provides 12-month visibility through 30 April 2027
- 3-year extension optionality contingent on Q1 performance under initial term
- Framework agreement creates scalable B2B channel for all brands on Xenitra platform
- Additional product lines may be added to Rockcheck partnership over time
- Platform model benefits from each new brand partner added to the B2B channel
The validation of Xenitra as an authorised supplier to a conglomerate generating revenues exceeding 1 trillion RMB annually enhances the company’s value proposition when negotiating with prospective brand partners seeking China market entry. The combination of e-commerce distribution and direct B2B access into large corporate groups provides optionality that standalone e-commerce platforms cannot replicate.
Rockcheck’s deep expertise in high-velocity nutritional products and Danone’s market-leading position in infant formula provide management with confidence that sales targets under the agreement can be met. The existing track record of more than $10 million AUD in FY26 sales to date supports this outlook.
The partnership positions Xenitra to execute on what management describes as a clearly defined strategy for driving towards profitability, with the framework creating a foundation that can scale as the company adds brand partners and product lines to its China distribution ecosystem.
Want the Next Consumer Deal in Your Inbox?
Join 20,000+ investors receiving FREE ASX news alerts within minutes of release, complete with in-depth analysis. Big News Blast delivers breaking consumer sector announcements and expert coverage straight to your inbox. Click the “Free Alerts” button to start receiving market-moving news the moment it breaks.